Legal Representation
Attorney
Michael J. Ryan, Jr.
USPTO Deadlines
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 22, 2010 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Feb 22, 2010 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 22, 2009 | EX5G | S | EXTENSION 5 GRANTED | Loading... |
| Jul 20, 2009 | EXT5 | S | EXTENSION 5 FILED | Loading... |
| Jul 20, 2009 | EEXT | I | TEAS EXTENSION RECEIVED | Loading... |
| Jan 8, 2009 | EX4G | S | EXTENSION 4 GRANTED | Loading... |
| Jan 7, 2009 | EXT4 | S | EXTENSION 4 FILED | Loading... |
| Jan 7, 2009 | EEXT | I | TEAS EXTENSION RECEIVED | Loading... |
| Jul 22, 2008 | EX3G | S | EXTENSION 3 GRANTED | Loading... |
| Apr 14, 2008 | EXT3 | S | EXTENSION 3 FILED | Loading... |
| Jul 22, 2008 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jul 14, 2008 | EEXT | I | TEAS EXTENSION RECEIVED | Loading... |
| Feb 14, 2008 | EX2G | S | EXTENSION 2 GRANTED | Loading... |
| Jan 23, 2008 | EXT2 | S | EXTENSION 2 FILED | Loading... |
| Jan 23, 2008 | I | PAPER RECEIVED | Loading... | |
| Jul 23, 2007 | EX1G | S | EXTENSION 1 GRANTED | Loading... |
| Jul 23, 2007 | EXT1 | S | EXTENSION 1 FILED | Loading... |
| Jul 23, 2007 | EEXT | I | TEAS EXTENSION RECEIVED | Loading... |
| Jan 23, 2007 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 31, 2006 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 11, 2006 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Sep 14, 2006 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Sep 1, 2006 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 26, 2006 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 26, 2006 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 15, 2006 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | Loading... |
Detailed Classifications
Class 005
Pharmaceutical for the treatment of auto-immune disorders, dermatological disorders, central nervous system diseases and disorders; and an anti-cancer agent
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005